Life Science and Medical News from Around the Globe
Four Studies by Students/Fellow in Professor Lorraine O’Driscoll’s Laboratory at Trinity College Dublin Are Presented at International Society for Extracellular Vesicles (ISEV) 2020 Virtual Annual Meeting (July 20-22)
Professor Lorraine O’Driscoll (photo), PhD, is Professor in Pharmacology and Irish Research Council Advanced Laureate at the School of Pharmacy and Pharmaceutical Sciences, and the Trinity Biomedical Sciences Institute of Trinity College Dublin in Ireland. Dr. O’Driscoll (https://pharmacy.tcd.ie/staff/odriscoll-cv.php?uname=lodrisc) (https://www.tcd.ie/research/profiles/?profile=lodrisc) is also the Coordinator and Principal Investigator of the TRAIN-EV Program (http://train-ev.eu/), which provides training to 15 PhD students in extracellular vesicles (EVs) for benefit in health and disease. Dr. O’Driscoll’s research group focuses on diagnostic, prognostic, and predictive biomarkers; discovering new therapeutic targets; cancer cells’ communication via extracellular vesicles (EVs), as well as the potential uses of EVs from mesenchymal stem cells (MSCs) in regenerative medicine and improving infant milk formula (IMF) by understand milk EVs. Three of Dr. O’Driscoll’s PhD students and one of her post-doctoral research fellows are presenting posters at the International Society for Extracellular Vesicles (ISEV) Virtual Annual Meeting (July 20-22) (https://www.eventscribe.com/2020/ISEV/). These four posters focus on EV release in triple-negative breast cancer, EV release inhibition in prostate cancer, analysis of EVs from drug-resistant and drug-sensitive cancer cells as potential predictive biomarkers in liquid biopsy, and optimizing methods for the separation and characterization of EVs from skim milk and infant milk formula. PhD student Niamh McNamee presented a poster (PF08.02) titled “Inhibition of Extracellular Vesicles in Triple-Negative Breast Cancer.” In her introduction, Ms. McNamee noted that triple-negative breast cancer (TNBC) is the most aggressive from of breast cancer.